LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermolysis Bullosa Dystrophica
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Trial Timeline
Oct 5, 2010 → Mar 9, 2022
NCT ID
NCT01263379About LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets is a phase 1/2 stage product being developed by Abeona Therapeutics for Epidermolysis Bullosa Dystrophica. The current trial status is completed. This product is registered under clinical trial identifier NCT01263379. Target conditions include Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01263379 | Phase 1/2 | Completed |
Competing Products
13 competing products in Epidermolysis Bullosa Dystrophica
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efgartigimod | Argenx | Phase 1/2 | 38 |
| KB803 + Placebo | Krystal Biotech | Phase 3 | 74 |
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 38 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 74 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 74 |
| SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%) | Amicus Therapeutics | Phase 2 | 49 |
| SD-101-6.0 cream + Placebo (SD-101-0.0) cream | Amicus Therapeutics | Phase 3 | 74 |
| SD-101-6.0 cream | Amicus Therapeutics | Phase 3 | 74 |
| SD-101 dermal cream (6%) | Amicus Therapeutics | Phase 2 | 49 |
| EB-101 | Abeona Therapeutics | Phase 3 | 69 |
| EB-101 Surgical application of RDEB wounds | Abeona Therapeutics | Phase 3 | 69 |
| VPD-737 | Vyne Therapeutics | Phase 2 | 44 |
| Serlopitant Tablet + Placebo Oral Tablet | Vyne Therapeutics | Phase 2 | 44 |